Want to see HK:6990 full AI Analyst Report?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Ratios
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Ratios
HK:6990's free cash flow for Q2 2026 was $156.14M. For the 2026 fiscal year, HK:6990's free cash flow was decreased by $-13.26M and operating cash flow was $169.40M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.13 | 4.31 | 2.53 | 0.08 | 0.09 |
| Quick Ratio | 4.89 | 4.18 | 2.47 | 0.07 | 0.07 |
| Cash Ratio | 3.32 | 1.66 | 1.41 | 0.03 | 0.02 |
| Solvency Ratio | -0.25 | -0.18 | -0.42 | -0.13 | -0.20 |
| Operating Cash Flow Ratio | -0.18 | -0.53 | 0.05 | -0.06 | -0.12 |
| Short-Term Operating Cash Flow Coverage | -1.84 | 0.00 | 0.00 | -0.09 | -0.18 |
| Net Current Asset Value | $ 4.03B | $ 2.53B | $ 1.63B | $ -3.89B | $ -608.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.03 | 0.02 | 3.04 | 2.94 |
| Debt-to-Equity Ratio | 0.02 | 0.04 | 0.03 | -0.93 | -0.90 |
| Debt-to-Capital Ratio | 0.02 | 0.04 | 0.03 | -14.23 | -9.45 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.23 | 1.29 | 1.51 | -0.31 | -0.31 |
| Debt Service Coverage Ratio | -2.65 | -45.20 | -4.92 | -0.13 | -0.26 |
| Interest Coverage Ratio | -75.71 | -55.69 | -5.37 | -2.65 | -7.21 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 1.67 | 0.62 |
| Interest Debt Per Share | 0.41 | 0.59 | 0.79 | 14.66 | 5.17 |
| Net Debt to EBITDA | 13.01 | 25.69 | 4.89 | -8.24 | -3.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 71.86% | 65.89% | 49.28% | 65.57% | 35.68% |
| EBIT Margin | -16.99% | -7.18% | -24.89% | -52.06% | -2512.37% |
| EBITDA Margin | -12.11% | -2.45% | -20.01% | -43.68% | -2441.47% |
| Operating Profit Margin | -22.65% | -10.94% | -29.38% | -49.00% | -2512.37% |
| Pretax Profit Margin | -17.29% | -7.37% | -30.36% | -70.57% | -2752.91% |
| Net Profit Margin | -18.56% | -13.80% | -37.27% | -76.64% | -2752.91% |
| Continuous Operations Profit Margin | -18.56% | -13.80% | -37.27% | -76.64% | -2752.91% |
| Net Income Per EBT | 107.36% | 187.15% | 122.76% | 108.59% | 100.00% |
| EBT Per EBIT | 76.32% | 67.43% | 103.33% | 144.03% | 109.57% |
| Return on Assets (ROA) | -6.38% | -6.25% | -16.36% | -62.04% | -87.79% |
| Return on Equity (ROE) | -7.85% | -8.06% | -24.65% | 19.10% | 26.99% |
| Return on Capital Employed (ROCE) | -9.35% | -6.11% | -18.86% | 12.41% | 24.75% |
| Return on Invested Capital (ROIC) | -9.09% | -6.04% | -18.44% | 195.82% | 268.79% |
| Return on Tangible Assets | -6.38% | -6.31% | -16.54% | -64.76% | -87.84% |
| Earnings Yield | -0.47% | -5.57% | -23.60% | -35.68% | -18.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 132.98 | 26.54 | 0.00 | 0.00 | 1.14 |
| Payables Turnover | 10.85 | 2.33 | 2.04 | 1.83 | 0.11 |
| Inventory Turnover | 2.40 | 5.97 | 12.40 | 5.26 | 0.69 |
| Fixed Asset Turnover | 2.85 | 2.68 | 2.35 | 1.32 | 0.05 |
| Asset Turnover | 0.34 | 0.45 | 0.44 | 0.81 | 0.03 |
| Working Capital Turnover Ratio | 0.60 | 0.88 | -1.44 | -0.36 | 0.00 |
| Cash Conversion Cycle | 120.96 | -81.45 | -149.45 | -129.74 | -2556.16 |
| Days of Sales Outstanding | 2.74 | 13.75 | 0.00 | 0.00 | 319.99 |
| Days of Inventory Outstanding | 151.85 | 61.17 | 29.45 | 69.40 | 531.37 |
| Days of Payables Outstanding | 33.64 | 156.37 | 178.90 | 199.14 | 3407.52 |
| Operating Cycle | 154.60 | 74.92 | 29.45 | 69.40 | 851.36 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.78 | -1.94 | 0.32 | -1.25 | -0.88 |
| Free Cash Flow Per Share | -1.33 | -2.30 | -0.12 | -1.44 | -1.04 |
| Dividend Paid and CapEx Coverage Ratio | -1.43 | -5.30 | 0.72 | -6.95 | -5.59 |
| Capital Expenditure Coverage Ratio | -1.43 | -5.30 | 0.72 | -6.95 | -5.59 |
| Operating Cash Flow Coverage Ratio | -2.04 | -3.39 | 0.99 | -0.09 | -0.18 |
| Operating Cash Flow to Sales Ratio | -0.09 | -0.22 | 0.04 | -0.34 | -16.27 |
| Free Cash Flow Yield | -0.38% | -10.66% | -0.93% | -17.94% | -12.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -212.86 | -17.96 | -4.24 | -2.80 | -5.39 |
| Price-to-Sales (P/S) Ratio | 39.59 | 2.48 | 1.58 | 2.15 | 148.36 |
| Price-to-Book (P/B) Ratio | 16.74 | 1.45 | 1.04 | -0.54 | -1.45 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -265.74 | -9.38 | -107.21 | -5.57 | -7.74 |
| Price-to-Operating Cash Flow Ratio | -451.82 | -11.15 | 40.85 | -6.38 | -9.12 |
| Price-to-Earnings Growth (PEG) Ratio | -5.55 | 0.31 | -0.36 | -0.06 | 0.00 |
| Enterprise Value Multiple | -313.85 | -75.48 | -3.00 | -13.16 | -9.72 |
| Enterprise Value | 78.22B | 3.58B | 923.87M | 4.62B | 1.19B |
| EV to EBITDA | -313.85 | -75.48 | -3.00 | -13.16 | -9.72 |
| EV to Sales | 38.01 | 1.85 | 0.60 | 5.75 | 237.42 |
| EV to Free Cash Flow | -255.16 | -7.00 | -40.72 | -14.92 | -12.38 |
| EV to Operating Cash Flow | -433.83 | -8.32 | 15.51 | -17.06 | -14.60 |
| Tangible Book Value Per Share | 21.11 | 14.75 | 12.47 | -15.14 | -5.51 |
| Shareholders’ Equity Per Share | 21.11 | 14.93 | 12.69 | -14.95 | -5.51 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | -0.87 | -0.23 | -0.09 | 0.00 |
| Revenue Per Share | 8.93 | 8.72 | 8.39 | 3.72 | 0.05 |
| Net Income Per Share | -1.66 | -1.20 | -3.13 | -2.85 | -1.49 |
| Tax Burden | 1.07 | 1.87 | 1.23 | 1.09 | 1.00 |
| Interest Burden | 1.02 | 1.03 | 1.22 | 1.36 | 1.10 |
| Research & Development to Revenue | 0.64 | 0.62 | 0.67 | 1.05 | 22.51 |
| SG&A to Revenue | 0.14 | 0.07 | 0.04 | 0.03 | 2.27 |
| Stock-Based Compensation to Revenue | 0.08 | 0.08 | 0.08 | 0.02 | 0.25 |
| Income Quality | 0.51 | 3.01 | -0.13 | 0.48 | 0.47 |
Currency in CNY